Hybrid red blood cell membrane coated porous silicon nanoparticles functionalized with cancer antigen induce depletion of T cells.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
21 Sep 2020
21 Sep 2020
Historique:
received:
06
07
2020
accepted:
16
09
2020
entrez:
6
5
2022
pubmed:
23
9
2020
medline:
23
9
2020
Statut:
epublish
Résumé
Erythrocyte-based drug delivery systems have been investigated for their biocompatibility, long circulation time, and capability to transport cargo all around the body, thus presenting enormous potential in medical applications. In this study, we investigated hybrid nanoparticles consisting of nano-sized autologous or allogeneic red blood cell (RBC) membranes encapsulating porous silicon nanoparticles (PSi NPs). These NPs were functionalized with a model cancer antigen TRP2, which was either expressed on the surface of the RBCs by a cell membrane-mimicking
Identifiants
pubmed: 35515680
doi: 10.1039/d0ra05900e
pii: d0ra05900e
pmc: PMC9056825
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35198-35205Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Pharm Res. 2012 Mar;29(3):837-46
pubmed: 22033881
Theranostics. 2015 Apr 27;5(8):863-81
pubmed: 26000058
Cancer Manag Res. 2018 Oct 29;10:4945-4957
pubmed: 30464595
Hepatology. 2008 Sep;48(3):978-90
pubmed: 18712788
Theranostics. 2016 Apr 28;6(7):1004-11
pubmed: 27217833
J Control Release. 2016 Mar 10;225:230-9
pubmed: 26826307
Adv Mater. 2017 Apr;29(16):
pubmed: 28199033
J Leukoc Biol. 2002 Apr;71(4):652-8
pubmed: 11927652
Curr Opin Struct Biol. 2009 Oct;19(5):507-14
pubmed: 19699080
Adv Mater. 2017 Mar;29(11):
pubmed: 28112838
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):88-103
pubmed: 26941164
Biomaterials. 2014 Nov;35(33):9224-35
pubmed: 25123922
RSC Adv. 2019 Sep 4;9(48):27911-27926
pubmed: 35530495
Biomaterials. 2016 Jul;94:93-104
pubmed: 27107168
Int J Pharm. 2013 Feb 25;443(1-2):39-49
pubmed: 23305866
Blood. 2012 Aug 9;120(6):1237-45
pubmed: 22760781
Adv Mater. 2017 Feb;29(7):
pubmed: 28009461
Nano Lett. 2013 Jun 12;13(6):2875-83
pubmed: 23647405
Adv Mater. 2013 Jul 12;25(26):3549-53
pubmed: 23712782
ACS Nano. 2019 Jun 25;13(6):6477-6490
pubmed: 31100004
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13481-6
pubmed: 25197051
ACS Biomater Sci Eng. 2018 Apr 9;4(4):1471-1478
pubmed: 30159384
Oncogene. 2005 Aug 4;24(33):5226-34
pubmed: 15897911
Nat Commun. 2018 Jul 11;9(1):2684
pubmed: 29992966
Int J Pharm. 2016 Sep 25;511(2):794-803
pubmed: 27484836
J Biol Chem. 1962 Jun;237:1992-2000
pubmed: 13891108
RSC Adv. 2018 Jun 1;8(36):20068-20076
pubmed: 35541656
J Exp Med. 1987 Feb 1;165(2):302-19
pubmed: 3029267
Biomaterials. 2014 Aug;35(26):7488-500
pubmed: 24906344
ACS Nano. 2010 Jun 22;4(6):3023-32
pubmed: 20509673
J Immunother. 2006 May-Jun;29(3):294-305
pubmed: 16699372
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E60-8
pubmed: 23248266
Sci Rep. 2015 Oct 29;5:15907
pubmed: 26511151
Cell Physiol Biochem. 2017;42(3):1127-1138
pubmed: 28668965
EMBO J. 1992 Feb;11(2):519-26
pubmed: 1537333
Transfusion. 2016 Apr;56(4):905-16
pubmed: 26843479
Biomaterials. 2013 Oct;34(31):7776-89
pubmed: 23866976
Small. 2017 Sep;13(33):
pubmed: 28714245
J Immunol Methods. 1991 Mar 1;137(1):79-87
pubmed: 1901329
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3157-3162
pubmed: 28270614
Nucl Med Biol. 2020 May - Jun;84-85:102-110
pubmed: 32334356
Langmuir. 2009 Sep 1;25(17):9847-56
pubmed: 19705885
Biomaterials. 2020 Jul;245:119983
pubmed: 32229333
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5
pubmed: 21690347
J Exp Med. 1996 Dec 1;184(6):2207-16
pubmed: 8976176
Nanoscale. 2014 Mar 7;6(5):2730-7
pubmed: 24463706
Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21495-9
pubmed: 20018694
Nanomedicine (Lond). 2014 Apr;9(4):535-54
pubmed: 24787441
J Am Chem Soc. 2011 Mar 30;133(12):4476-83
pubmed: 21370858
Nano Lett. 2019 Sep 11;19(9):6647-6657
pubmed: 31409072